Abu Dhabi Launches Life Sciences Cluster to Advance Healthcare Innovation Worldwide, tapping a $25.3 trillion market
Abu Dhabi has launched the groundbreaking life sciences cluster, reinforcing its position as a global hub for biotechnology, MedTech, and digital health. Developed by the Abu Dhabi Department of Economic Development, Abu Dhabi Investment Office (ADIO) and the Department of Health – Abu Dhabi, the Health, Endurance, Longevity, and Medicine (HELM) cluster is designed to drive healthcare innovation, attract international investment, and deliver lasting benefits to global populations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250416840862/en/
Abu Dhabi Launches Life Sciences Cluster to Advance Healthcare Innovation Worldwide, tapping a $25.3 trillion market (Photo: AETOSWire)
Announced during Abu Dhabi Global Health Week, the HELM cluster will serve as a platform for the research, development, manufacturing and commercialisation of advanced health and life science solutions. From AI-powered diagnostics and pharmaceutical manufacturing to gene therapies and precision medicine, the cluster is poised to enable global companies to transform breakthrough science into scalable and accessible, patient-focused solutions.
With its world-class infrastructure, progressive regulations, and strategic geographic location, Abu Dhabi offers unparalleled access to global markets. The emirate’s multicultural talent base, advanced biomanufacturing facilities, and commitment to innovation make it an ideal launchpad for life sciences companies looking to scale globally.
His Excellency Ahmed Jasim Al Zaabi, Chairman of the Abu Dhabi Department of Economic Development, said: “The Abu Dhabi Health, Endurance, Longevity, and Medicine (HELM) cluster will provide global and local stakeholders with a wide range of benefits, including access to cutting-edge technologies, world-class infrastructure and progressive regulatory frameworks. By creating a globally competitive life sciences hub, we are not only accelerating economic growth and diversification, but we are also ensuring that Abu Dhabi remains at the forefront of developing breakthrough healthcare solutions that will benefit humanity at large.”
Built to meet the rising global demand for advanced healthcare, the cluster is designed to tackle some of the world’s most pressing health challenges, including chronic and non-communicable diseases, which account for over 70% of deaths globally, as well as the healthcare needs of ageing populations. It is tapping growth opportunities in the global healthcare market, which is projected to reach $25.3 trillion (AED93 trillion) by 2045.
His Excellency Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, said: “The launch of Abu Dhabi’s Health, Endurance, Longevity, and Medicine cluster is a bold leap forward in how the world delivers healthcare. We are not just investing in infrastructure, we’re investing in human potential, in breakthroughs that will redefine longevity, and in solutions that will reach far beyond our borders. This is where innovation meets impact.”
Leveraging an innovation-friendly regulatory framework, Abu Dhabi empowers companies to bring breakthrough technologies to market faster, shaping the future of healthcare at speed and scale. Its AI-powered health system and leadership in precision medicine create an environment where innovation thrives across the entire value chain.
As home to one of the world’s largest national genomics programme, the emirate supports research and development by fostering insights from a uniquely diverse genomic landscape, accelerating innovation and advancing the global shift toward personalised treatments. At the same time, Abu Dhabi is strengthening its role in the global pharmaceutical supply chain, offering reliable infrastructure, strategic connectivity, and long-term partnership opportunities for companies navigating an increasingly complex global landscape.
By 2045, the HELM cluster is expected to contribute $25.6 billion (AED 94 billion) to Abu Dhabi’s GDP, attract $11.5 billion (AED 42 billion) in investment, and create 30,000 high-value jobs, supporting the diversification of the emirate’s economy while enabling long-term global health impact.
The cluster is part of Abu Dhabi’s broader strategy to lead globally in emerging industries. It follows the successful launch of the Smart and Autonomous Vehicle Industries (SAVI) cluster in 2023, which addresses smart urban mobility across air, land, and sea– and the AgriFood Growth and Water Abundance (AGWA) cluster in 2024, which addresses food security and water sustainability challenges.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250416840862/en/
Contacts
Chase Burns
ADIO@edelman.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom